Two people live in the same building after a water leak. One develops persistent headaches, fatigue, and brain fog that linger for months. The other notices nothing unusual and feels completely fine. The mold exposure was the same. The outcomes were not. This kind of disparity — one person floored by something another person shrugs off — shows up repeatedly with chemical sensitivities, alcohol, caffeine, perfumes, pesticides, and air pollution. It has a biological explanation, and much of it comes down to how efficiently the liver processes and eliminates toxic compounds.
Detoxification is not a trend or a marketing concept. It’s a genuine, continuous biological process happening in your liver, kidneys, lungs, and gut around the clock. Every substance that enters the body — whether it’s a glass of wine, a pesticide residue on produce, a cleaning product inhaled while scrubbing a bathroom, or a metabolic byproduct of your own stress hormones — needs to be identified, processed, and cleared. The enzymes that do this work are encoded by specific genes, and the efficiency of those enzymes varies considerably from person to person based on their genetic variants.
Understanding where your detox system is strong and where it has bottlenecks doesn’t just explain past reactions. It gives you a practical framework for reducing your toxic load, supporting the pathways that need help, and avoiding the exposures most likely to cause problems for your specific genetic makeup.
Contents
How the Body’s Detox System Actually Works
The liver processes toxins in two sequential stages, commonly called Phase I and Phase II detoxification. These phases don’t work independently — they’re a relay system, and what happens in Phase I directly determines the burden placed on Phase II.
Phase I is handled primarily by a large family of enzymes called cytochrome P450s, encoded by the CYP genes. These enzymes chemically modify toxins to make them more reactive — essentially preparing them for the next step. The problem is that this process can temporarily produce intermediate compounds that are more chemically active than the original toxin. If Phase I is running fast and Phase II can’t keep up, those reactive intermediates accumulate, and that’s where cellular damage can occur. Conversely, if Phase I is sluggish, toxins sit in circulation longer than they should.
Phase II picks up where Phase I leaves off. A different set of enzymes — including glutathione S-transferases (GSTs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and N-acetyltransferases (NATs) — attach molecules to those reactive intermediates, neutralizing them and making them water-soluble so the kidneys and bile can eliminate them. This conjugation process is where most genetic variation in detox capacity concentrates, and it’s where the clearest differences between high- and low-sensitivity individuals tend to emerge.
The CYP Genes: Your Phase I Enzymes
The CYP gene family — which includes CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C9, CYP2C19, and CYP3A4 — is responsible for metabolizing an enormous range of substances. These include environmental pollutants like polycyclic aromatic hydrocarbons (found in cigarette smoke and grilled meat), pharmaceutical drugs, alcohol metabolites, hormones, and dozens of other compounds the body encounters daily.
Variants in these genes can make the enzymes faster or slower than average, and the consequences are meaningful. A person with a slow CYP1A2 variant clears caffeine more slowly, which is why one cup of coffee that leaves most people unaffected can make someone else jittery and sleepless for hours. A person with a rapid CYP2C9 variant may metabolize certain medications too quickly for standard doses to be effective. CYP3A4 is particularly significant because it handles metabolism of roughly half of all pharmaceutical drugs — variants here affect how drugs work and what side effects emerge at standard doses.
CYP1B1 has a particular relevance to estrogen metabolism: variants in this gene affect how estrogens are converted to different metabolites in the body, which has downstream implications for hormone balance, breast tissue health, and response to hormone exposures from both endogenous and environmental sources.
Phase II Genes: Where Toxins Are Neutralized and Cleared
Even the most robust Phase I system creates reactive intermediates that need rapid conjugation. The genes encoding Phase II enzymes determine how efficiently that happens. Several of the most clinically significant are worth understanding in detail.
The glutathione S-transferase family — including GSTA1 and GSTP1 — encodes enzymes that conjugate reactive compounds with glutathione, the body’s most important antioxidant molecule. Variants that reduce GST enzyme activity leave reactive toxins in circulation longer and deplete glutathione reserves more rapidly. This is particularly relevant for people with chemical sensitivities, because the glutathione system is a primary defense against oxidative damage from environmental exposures. The GCLC gene encodes the rate-limiting enzyme in glutathione synthesis itself — variants here can reduce the body’s total glutathione production capacity.
The NAT2 gene encodes an enzyme involved in a process called acetylation, which neutralizes aromatic amines found in cigarette smoke, some food preservatives, and certain drugs. NAT2 comes in clearly defined “slow” and “fast” acetylator phenotypes. Slow acetylators — which represent roughly half the population in many ethnic groups — clear these compounds more slowly and have elevated exposure to reactive intermediates during that extended clearance time.
The UGT1A1 gene encodes an enzyme that conjugates bilirubin, certain hormones, and various drugs and environmental chemicals for elimination through bile. Reduced UGT1A1 activity is what causes Gilbert’s syndrome, a common benign condition where bilirubin levels run slightly elevated. But the reduced activity has implications beyond bilirubin — it can affect how various toxins and medications are processed and cleared.
Alcohol, Mold, and Chemical Sensitivity: Where Genetics Makes the Difference
The genes ADH1B and ALDH2 specifically govern how the body metabolizes alcohol. ADH1B encodes the enzyme that converts alcohol into acetaldehyde — a highly toxic intermediate — and ALDH2 encodes the enzyme that converts acetaldehyde into the far less harmful acetate. The well-known “Asian flush” reaction, where some people experience facial flushing, rapid heart rate, and nausea after even small amounts of alcohol, is caused by a common ALDH2 variant that significantly impairs this second conversion step. Acetaldehyde builds up faster than it can be cleared, causing those acute symptoms. But slower, less dramatic versions of impaired alcohol clearance occur across other genetic variants and ancestries too.
Mold sensitivity is more complex because it involves both the direct toxicity of mycotoxins — chemical compounds produced by mold species — and an immune response. The detox genes most relevant here are the CYP enzymes and GSTs, which process mycotoxins for elimination, along with the NFE2L2 gene, which encodes NRF2. NRF2 is a master regulatory protein that activates dozens of downstream detox and antioxidant genes in response to oxidative stress. Variants that reduce NRF2 activity mean the body’s stress-response detox system fires less robustly when needed most — which is precisely during heavy mold or chemical exposure.
The PON1 gene adds another layer: it encodes paraoxonase 1, an enzyme primarily responsible for detoxifying organophosphate pesticides and oxidized lipids. PON1 variants that reduce enzyme activity result in less efficient clearance of pesticide residues and may increase cardiovascular risk from oxidized cholesterol — a connection that links environmental chemical exposure directly to long-term disease risk.
The COMT and AHR Connection
Two additional genes in the detox network deserve specific attention. The COMT gene — which also appears in mental health and hormonal contexts — encodes an enzyme that breaks down catecholamines (stress hormones like dopamine, norepinephrine, and adrenaline) as well as catechol estrogens. Slow COMT variants mean these compounds clear more slowly, which can amplify stress responses, affect mood stability, and allow certain estrogen metabolites to accumulate. Because COMT is involved in processing internal metabolic byproducts rather than only external toxins, it links the detox pathway to neurological and hormonal function in ways that aren’t always obvious.
The AHR gene (aryl hydrocarbon receptor) encodes a protein that acts as a sensor for certain environmental pollutants — particularly dioxins, polychlorinated biphenyls (PCBs), and aromatic hydrocarbons in combustion products and industrial chemicals. When AHR detects these compounds, it activates Phase I CYP enzymes to begin metabolizing them. Variants in AHR affect how sensitively this system responds, which in turn determines how aggressively Phase I metabolism fires in response to environmental exposures. An overactive AHR response can push Phase I faster than Phase II can manage, creating the reactive intermediate buildup discussed earlier.
What Supporting Your Detox Genes Actually Looks Like
Genetic variants in detox pathways are not something to panic about. The body has considerable redundancy built into these systems, and meaningful support is available through diet, targeted supplementation, and thoughtful reduction of unnecessary exposures.
Cruciferous vegetables — broccoli, Brussels sprouts, cauliflower, cabbage — contain sulforaphane and indole-3-carbinol, compounds that activate NRF2 and upregulate multiple Phase II enzymes. N-acetylcysteine (NAC) is a precursor to glutathione synthesis, directly supporting the GST pathway. Selenium supports glutathione peroxidase activity. Milk thistle (silymarin) is one of the better-studied botanical supports for liver function and Phase II capacity. These are not exotic interventions — they’re evidence-based supports that become meaningfully more or less relevant depending on a person’s specific genetic profile.
Knowing which CYP enzymes run fast or slow also has practical implications for medication use. Many drug interactions occur because two medications compete for the same CYP enzyme, and if that enzyme is already running slowly due to a genetic variant, the interaction risk is compounded. This is why pharmacogenomic testing — which overlaps significantly with detox genetics — has become an increasingly important tool in medication management.
Understanding Your Detox Genetics
The SelfDecode Detox Pathway Report provides an in-depth analysis of 21 genes governing your body’s Phase I and Phase II detoxification systems, including CYP1A1, CYP1A2, CYP3A4, GSTA1, GSTP1, NAT2, UGT1A1, ADH1B, ALDH2, PON1, COMT, NFE2L2, and AHR. It covers how your body processes more than 50 specific toxins — from alcohol and caffeine to mold toxins, pesticides, and air pollutants — and delivers personalized, DNA-based recommendations for diet, supplements, and life habits. Compatible with existing 23andMe and AncestryDNA raw data.